Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.

For RFS, there is a weak trend favoring the Cy-pretreated participants (HR 0.79, 95% CI, 0.52 to 1.19, Supplementary Fig. 1B ).

also in 266 other papers

We also ran multivariable analysis for RFS excluding arm, and no covariates were significant, but age, sex, and advanced disease status approached significance (Supplementary Table 6 ).

also in 1,426 other papers